Sheh Rawat1, Parveen Ahlawat1, Anjali Kakria1, Gaurav Kumar2, Ranga Rao Rangaraju2, Abhishek Puri3, Manoj Pal1, Deepika Chauhan1, Bharti Devnani4, Pranav Chadha5. 1. Department of Radiation Oncology, Rajiv Gandhi Cancer Institute and Research Centre, New Delhi, India. 2. Department of Medical Oncology, Max Super Specialty Hospital, Shalimar Bagh, New Delhi, India. 3. Department of Radiation Oncology, Fortis Hospital, Mohali, Punjab, India. 4. Department of Radiotherapy, All India Institute of Medical Sciences, New Delhi, India. 5. Department of Radiation Oncology, Kokilaben Dhirubhai Ambani Hospital & Medical Research Institute, Mumbai, Maharashtra, India.
Abstract
AIM: To present a direct comparison between chemotherapy-enhanced radiotherapy (CERT) and biotherapy-enhanced radiotherapy (BERT) in locally advanced head and neck cancer. METHODS: It is a retrospective analysis of 53 patients with locally advanced head and neck cancer treated from August 2006 to December 2008. For CERT, patients received weekly cisplatin (40 mg/m2 ) and for BERT, a loading dose of 400 mg/m2 of cetuximab given one week prior to radiotherapy followed by 250 mg/m2 given weekly along with radiotherapy. Disease-free survival (DFS) and overall survival (OS) were computed with Kaplan-Meier curve with log-rank test for comparison between the two groups. Multivariate Cox proportional hazards regression analysis was performed to estimate the impact of known relevant prognostic factors on DFS and OS. RESULTS: The median DFS was significantly better with CERT than BERT group (50.82 vs 11.66 months; P = 0.031). The 3 years DFS was significantly higher in CERT group than in BERT group (60.0% vs 14.3%; P = 0.022). The median OS was significantly better with CERT than BERT group (53.61 vs 32.55 months; P = 0.044). The 3 years OS was also significantly higher in CERT group than in BERT group (74.0% vs 42.1%; P = 0.032). There were no significant differences in acute toxicities of all grade and grade ≥3 between the two groups. The compliance to treatment and assisted feeding dependency for more than 6 months duration were also not significantly different. CONCLUSION: CERT is associated with better outcome with no significantly increased acute toxicities compared to BERT.
AIM: To present a direct comparison between chemotherapy-enhanced radiotherapy (CERT) and biotherapy-enhanced radiotherapy (BERT) in locally advanced head and neck cancer. METHODS: It is a retrospective analysis of 53 patients with locally advanced head and neck cancer treated from August 2006 to December 2008. For CERT, patients received weekly cisplatin (40 mg/m2 ) and for BERT, a loading dose of 400 mg/m2 of cetuximab given one week prior to radiotherapy followed by 250 mg/m2 given weekly along with radiotherapy. Disease-free survival (DFS) and overall survival (OS) were computed with Kaplan-Meier curve with log-rank test for comparison between the two groups. Multivariate Cox proportional hazards regression analysis was performed to estimate the impact of known relevant prognostic factors on DFS and OS. RESULTS: The median DFS was significantly better with CERT than BERT group (50.82 vs 11.66 months; P = 0.031). The 3 years DFS was significantly higher in CERT group than in BERT group (60.0% vs 14.3%; P = 0.022). The median OS was significantly better with CERT than BERT group (53.61 vs 32.55 months; P = 0.044). The 3 years OS was also significantly higher in CERT group than in BERT group (74.0% vs 42.1%; P = 0.032). There were no significant differences in acute toxicities of all grade and grade ≥3 between the two groups. The compliance to treatment and assisted feeding dependency for more than 6 months duration were also not significantly different. CONCLUSION: CERT is associated with better outcome with no significantly increased acute toxicities compared to BERT.
Authors: Shilpa Bhatia; Jaspreet Sharma; Sanjana Bukkapatnam; Ayman Oweida; Shelby Lennon; Andy Phan; Dallin Milner; Nomin Uyanga; Antonio Jimeno; David Raben; Hilary Somerset; Lynn Heasley; Sana D Karam Journal: Clin Cancer Res Date: 2018-05-30 Impact factor: 12.531
Authors: William A Stokes; Whitney A Sumner; Kiersten L Breggren; John T Rathbun; David Raben; Jessica D McDermott; Gregory Gan; Sana D Karam Journal: Rep Pract Oncol Radiother Date: 2017-08-02
Authors: Govind Babu; Ankur Bahl; G S Bhattacharya; K T Bhowmik; P S Dattatraya; Nikhil Ghadyalpatil; S M Karandikar; Padmaj Kulkarni; Nithya Sridharan; Purvish Parikh; Kumar Prabhash; T Raja; S Rajasundaram; S Subramanian; Kaustav Talapatra; Ashok Vaid Journal: South Asian J Cancer Date: 2017 Oct-Dec